• Evogene received a Nasdaq notice granting an extra 180 days, until March 29, 2027, to regain the $1.00 minimum bid requirement.
• Compliance requires a closing bid of at least $1.00 for 10 consecutive business days during the extension period.
• Failure to regain compliance by the deadline could trigger a Nasdaq delisting determination.
• Evogene may consider a reverse share split if needed to cure the deficiency; the notice has no immediate trading impact.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609300715PR_NEWS_USPR_____LN60388) on September 30, 2026, and is solely responsible for the information contained therein.